AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer
[This corrects the article DOI: 10.1016/j.omton.2026.201253.].
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
[This corrects the article DOI: 10.1016/j.omton.2026.201253.].
Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.